Skip to search formSkip to main contentSkip to account menu
Glucocorticoid-induced osteoporosis
TLDR
In patients with rheumatoid arthritis, a treat-to-target strategy focusing on low disease activity including through the use of low dose of prednisone, is a key determinant of bone loss prevention.
View on Publisher
Therapeutic management of hypophosphatemic rickets from infancy to adulthood
TLDR
In this review, medical, dental, surgical, and contributions of various expertises to the treatment of HR are described, with an effort to highlight the importance of coordinated care.
View PDF
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
TLDR
It is recommended that the diagnosis of XLH is based on signs of rickets and/or osteomalacia in association with hypophosphataemia and renal phosphate wasting in the absence of vitamin D or calcium deficiency.
View on Springer
Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole
TLDR
Omeprazole use is associated with an increased risk of vertebral fractures in postmenopausal women and further studies are required to determine the mechanism of the association between the underlying gastric disease, omeprazoles use, and risk of osteoporotic fractures.
View on Springer
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis.
View on PubMed
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis.
View on PubMed
Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids
TLDR
Vertebral fracture assessment (VFA) is a convenient tool for the diagnosis of vertebral fracture in RA and presence of VF is inversely related to the use of DMARD and glucocorticoids, enhancing the hypothesis that an appropriate control of the disease may be a protective factor against bone fragility.
View on Springer
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
TLDR
This study shows that in patients intolerant to one AI, switching to another agent allows a higher proportion of patients to continue the therapy and maximize hormonal adjuvant therapy and disease outcome benefits.
View on Springer
Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
TLDR
This 2-year prospective study showed a significant increase in body weight at 1 year and 2 years, mostly due to a gain in fat mass and asignificant increase in BMD, in patients with SpA receiving anti-TNF-alpha treatment.
View on PubMed
Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License